FENG CHI BIOTECH CORP. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.7 TWD | +0.46% |
|
-5.86% | -2.25% |
| Apr. 08 | Feng Chi Biotech Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Feng Chi Biotech Corp. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 193M 5.99M | Sales 2023 | 181M 5.59M | Capitalization | 342M 10.59M |
|---|---|---|---|---|---|
| Net income 2022 | 24M 743K | Net income 2023 | 22M 682K | EV / Sales 2022 | 0.45 x |
| Net cash position 2022 | 222M 6.86M | Net cash position 2023 | 205M 6.35M | EV / Sales 2023 | 0.76 x |
| P/E ratio 2022 |
12.5
x | P/E ratio 2023 |
15.1
x | Employees | 32 |
| Yield 2022 |
6.75% | Yield 2023 |
4.73% | Free-Float | 72.3% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.46% | ||
| 1 week | -5.86% | ||
| Current month | -2.03% | ||
| 1 month | -5.03% | ||
| 3 months | -4.62% | ||
| 6 months | -8.63% | ||
| Current year | -2.25% |
1 week
21.20
22.15
1 month
21.2023.15
Current year
21.1524.40
1 year
21.1527.30
3 years
18.0032.75
5 years
18.0071.00
10 years
18.0071.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hung Ming Chang
CEO | Chief Executive Officer | - | 00-04-30 |
Mei Chen Lu
DFI | Director of Finance/CFO | - | 04-03-31 |
Pei I Lin
IRC | Investor Relations Contact | - | 15-10-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chun Cheng Wu
CHM | Chairman | - | 06-09-24 |
Chu Liu
BRD | Director/Board Member | - | 19-08-29 |
Pai Nien Chen
BRD | Director/Board Member | - | 19-08-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 21.7 | +0.46% | 2,706 |
| 24-06-04 | 21.6 | -2.48% | 2,101 |
| 24-06-03 | 22.15 | 0.00% | 28,007 |
| 24-05-31 | 22.15 | +0.45% | 19,446 |
| 24-05-30 | 22.05 | -4.34% | 32,255 |
End-of-day quote Taipei Exchange, June 04, 2024
More quotes
FENG CHI BIOTECH CORP. is a Taiwan-based Company mainly engaged in the production of medical testing reagents. The Companyâs products include prenatal and neonatal testing reagents and instruments, genetic testing analysis and development services, research instruments and reagents, industrial microbiology and food testing reagents, and among others. The company's products are mainly sold to Taiwan, China mainland, Japan, South Korea, Southeast Asia and India, as well as other overseas regions.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.25% | 10.28M | |
| -16.04% | 269M | |
| +26.13% | 77.74M | |
| +19.16% | 64.96M |
- Stock Market
- Equities
- 6744 Stock
